



Institutional Biosafety Committee Meeting Minutes

The meeting was called to order on 6/23/2026 at 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance

Voting Members Present:

Rachel Brownlee
Nicholas Carpino
Jeronimo Cello
Jorge Escobar
Hwan Kim
Christopher Kuhlow
Alyssa Tuthill
Dafang Wang

Non-Voting Attendees, Staff and Guests Present:

Rebecca Dahl
Lu-Ann Kozlowski
Aimee Minton

Recording:

Erin Augello

Items

1. Meeting called to order at 11:30AM

2. Next meeting date and general announcements

The next meeting date is 7/28/2026. Dr. Kim surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of minutes from last meeting

Review type: Full Committee Review

Action: **Approved**
Effective date: **6/23/2026**
Vote: **Total = 8; For = 8; Opposed = 0; Abstained = 0**

4. Continuing reviews requiring IBC review

This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202600006 Neurotransmitter Plasticity in Substance Use Disorder

PI:	Marta Pratelli
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: Stony Brook University, Grant Office ID: Funding Source ID: Name: Research Foundation of City University of New York,
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-1

Determination: Modifications Required

Modifications (If Applicable):

i. In section: BASIC INFORMATION

4. Summary of research

PI should write a brief description of rsNAM work

ii. In section: FUNDING SOURCES

1. Missing funding sources.

iii. In Section EXPOSURE ASSESSMENT AND PROTECTIVE EQUIPMENT

1. Please describe a contact time with 10% bleach.

iv. In section WASTE MANAGEMENT

1. & 3. Please describe a contact time with 10% bleach.

Effective Date: 6/30/2026

Project Expiration: 6/29/2027

Votes:

For:	8
Against:	0
Recused:	0
Absent:	2
Abstained:	0

b. PROTO202600019 WCG: Juno Therapeutics, Inc. - CA0881007

PI:	Michael Schuster
Submission Type:	Initial Protocol

Safety Review Type:	Biosafety
Funding:	Name: Juno Therapeutics, Grant Office ID: Funding Source ID: Unknown
Training:	PI and study staff need training including ELS 003 and EOS 004
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-2

Determination: Approved

Modifications (If Applicable):

i. Training is not up to date. Schuster requires ELS 003 and EOS 004.

ii. In section BASIC INFORMATION

4. Summary of research

Brief description of rsNAM work should be included

ii. In section: FUNDING SOURCES

Additional funding information is required.

iii. In Section BIOSAFETY SUMMARY

rsNAM section is not selected. Clarification is required regarding whether lentiviral work is performed on campus or whether all rsNAM work is performed at June Therapeutics.

iv. In section RISK GROUP AND CONTAINMENT PRACTICES

1. Lentivirus is used to produce the CAR-T cells, so the RG is 3

v. In section EXPOSURE ASSESSMENT AND PROTECTIVE EQUIPMENT

1. Provided response primarily discusses why exposure is unlikely and why the overall risk is considered negligible. Please revise this section to describe the potential consequences of exposure to the lentivirus-transduced CAR-T cells. For humans, this may include exposure to human-derived cellular material and bloodborne pathogens, accidental inoculation of viable genetically modified T cells, and theoretical transient persistence or engraftment of transferred cells

4. A new BSC certificate is required.

Effective Date: 6/30/2026

Project Expiration: 6/29/2027

Votes:

For:	7
Against:	0
Recused:	0
Absent:	2
Abstained:	0

c. PROTO202600021 RESQ132EX-NMIBC

PI:	Michael Hung
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	Name: ImmunityBio Incorporated

Training:	PI and study staff need training: ELS 002, ELS 003, ENV 001, ENV 005.
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-2

Determination: Modifications Required**Modifications (If Applicable):**

- i. Training is not up to date. staff require ELS 002, ELS 003, ENV 001, ENV 005
- ii. In section: BASIC INFORMATION
4. Please provide an additional description of the generation of recombinant Bacillus Calmette-Guérin (rBCG).
- iii. In section PROTOCOL TEAM MEMBERS
 1. Please clarify if Heather Cosgrove is involved in the proposed study. If so, please complete the form.
- iv. In section FUNDING SOURCES
 1. Please add funding sources.
- v. In section BACTERIA, YEASTS, FUNGI OR PARASITES
 1. BCG should be handled in BSL2.
- vi. In section BIOHAZARDS
 1. BCG should be handled in BSL2.
- vii. In section RECOMBINANT AND SYNTHETIC NUCLEIC ACIDS USAGE
 1. The NIH guidelines 3C for studies performing deliberate HGT into research participants of either:
 - a. recombinant nucleic acid molecules, or DNA, or RNA derived from synthetic nucleic acid molecules, or
 - b. synthetic nucleic acid molecules, or DNA, or RNA derived from synthetic nucleic acid molecules that meet any of the following criteria:
 - contain more than 100 nucleotides
 - possess biological properties that enable introduction of stable genetic modifications into the genome
 - have potential to replicate in a cell
 - can be translated or transcribed

Clarification is requested on whether the proposed studies fall under IIIC and, if so, which of the referenced categories they fall under.
- ix. In section RECOMBINANT AND SYNTHETIC NUCLEIC ACIDS WORK DESCRIPTION
 1. Clarification is required to understand how the rBCG is generated. In addition, it is unclear whether rBCG is created by the PI or acquired.
- x. In section EXPOSURE ASSESSMENT AND PROTECTIVE EQUIPMENT
 1. Please describe the potential consequences of aerosol exposure to BCG for laboratory personnel. Potential outcomes may include respiratory infection, localized pulmonary disease, and, in rare cases, disseminated infection, particularly in immunocompromised individuals.
 4. BSC certification date must be revised.
- xi. In section DUAL USE RESEARCH OF CONCERN
 5. Please provide a short description of why the proposed studies do not have DURC.

Effective Date: 6/30/2026**Project Expiration:** 6/29/2027

Votes:

For:	8
Against:	0
Recused:	0
Absent:	2
Abstained:	0

6. Amendments requiring IBC review

a. AMEND202500006 Full board review and continuing review

PI:	Peter Igarashi
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and staff need ELS 002, ELS 003, EOS 004, ENV 001, ENV 005.
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-2

Determination: Approved**Modifications (If Applicable):**

- i. Training is not up to date. Diao and Hausch require EOS 004. Curtis Chan requires ELS 002, ELS 003, EOS 004, ENV 001, ENV 005.
- ii. In section BACTERIA, YEASTS, FUNGI OR PARASITES
 2. Please clarify if additional E. coli strains are used in this protocol.
- iii. In section BIOHAZARDS
 2. Please clarify what constitutes BSL2+. In addition, please provide descriptions for E. coli and 293T.
- iv. In section RECOMBINANT AND SYNTHETIC NUCLEIC ACIDS WORK DESCRIPTION
 1. Please clarify what constitutes BSL A2+.
 8. Experimental protocols are documented. Please simplify and clarify what packaging systems are used in the protocol.
 9. Please clarify if any prior attempts have been made to express foreign genes from living organisms in the laboratory.
- v. In section EXPOSURE ASSESSMENT AND PROTECTIVE EQUIPMENT
 1. Please describe any risks associated with bloodborne pathogen exposure.
- vi. In section WASTE MANAGEMENT
 1. Please edit to include all proposed viral vectors.

Effective Date: 6/30/2026**Project Expiration:** 6/29/2027**Votes:**

For:	8
-------------	---

Against:	0
Recused:	0
Absent:	2
Abstained:	0

b. AMEND202600075 Personnel Addition

PI:	Alfredo Fontanini
Submission Type:	Amendment
Safety Review Type:	Biosafety
Funding:	None
Training:	PI and all laboratory staff have been trained
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-2

Determination: Approved**Modifications:** None**Effective Date:** 6/30/2026**Project Expiration:** 6/29/2027**Votes:**

For:	8
Against:	0
Recused:	0
Absent:	2
Abstained:	0

7. Review of incidents

None

8. Review of other agenda items

None

9. Inspection results

All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion items/readings (major and minor points of order)

None

11. Meeting adjourned at 12:23PM